Baricitinib

Baricitinib is a selective Janus kinase (JAK1 and JAK2) inhibitor used in the treatment of moderate-to-severe rheumatoid arthritis, alopecia areata, and COVID-19 in hospitalized adults. It reduces inflammation by blocking cytokine signaling pathways. Mediocon Inc supplies pharmaceutical-grade Baricitinib meeting IP/BP/EP/USP standards.

Key Features

• Selective JAK1/JAK2 inhibitor
• IP/BP/EP/USP compliant quality
• Rheumatoid arthritis and alopecia areata treatment
• Oral once-daily tablet formulation

Applications

• Oral tablets for rheumatoid arthritis
• Alopecia areata treatment
• COVID-19 hospitalized patient therapy
• Immunology research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings